SINOVAC
4.7.2022 13:32:06 CEST | Business Wire | Press release
A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific COVID-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunization strategy. This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005146/en/
In this study, a total of 300 healthy adult volunteers aged 18 and above who have been vaccinated with two or three doses of inactivated or mRNA COVID-19 vaccine will be recruited.
“As we know, vaccination is one of the most effective ways to cope with infectious diseases. Currently, Omicron continuously sweeps the world. I hope the clinical trial could strengthen and effectively promote vaccine research and vaccination administration,” Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, and Assistant Dean of Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine, The University of Hong Kong (HKUMed), stated in the ceremony.
“As one of the research sites of HKU, we are pleased to be part of this clinical trial project and contribute to the continuous research and development of vaccines and immunization strategies to help enhance health protection for people,” said Dr Kenneth Tsang.
“It is of great significance to cooperate with Professor Hung, HKU-CTC and Gleneagles to carry out the clinical trial of the COVID-19 inactivated vaccine as a booster shot against the Omicron strain. We hope to find a solution for Hong Kong and the globe to fight against the new viruses with the results of this trial,” said Ms. Cheryl Law, International Business Development Director of SINOVAC.
SINOVAC obtained the sample of the Omicron variant in early December 2021 and then actively promoted research and development of its inactivated COVID-19 vaccine (Omicron specific strain). Preclinical research demonstrated that the vaccine is safe and effective in animals. The Omicron strain booster immunization clinical trial was then approved by the HKU GHK Institutional Review Board (IRB) on 12th April 22 and by the Pharmacy and Poisons Board of Hong Kong on 14th April 22, allowing the carrying out of the clinical study on boosting the immunity of people against the new coronavirus strain in Hong Kong.
About Sinovac Biotech Ltd.
SINOVAC Biotech Ltd. (SINOVAC) is a China-based leading biopharmaceutical company that focuses on the research, innovation, manufacture, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against emerging infectious diseases such as COVID-19, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and enterovirus 71 (EV71), and other common infectious diseases such as viral hepatitis, seasonal influenza, pneumococcal pneumonia, poliomyelitis, varicella and mumps. SINOVAC is also exploring opportunities in the international market and is exporting it vaccines to tens of countries and international organizations. More information about SINOVAC can be found at www.sinovac.com .
About HKU Clinical Trials Centre
The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed. Since its establishment, HKU-CTC has already facilitated over a thousand of sponsored clinical studies and investigator-initiated clinical studies in collaboration with sponsors and investigators around the world.
About Gleneagles Hospital Hong Kong
Located at Wong Chuk Hang on Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital, providing 500 beds, cutting-edge medical technologies and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong’s top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner. More information on Gleneagles Hospital Hong Kong can be found at https://www.gleneagles.hk/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005146/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands GeoPurchase Audiences Globally, Unlocking Growth Opportunities for Marketers in Poland, Belgium, Mexico, and Indonesia22.6.2026 12:00:00 CEST | Press release
International expansion helps advertisers target audiences based on local consumer demand NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its GeoPurchase audiences into Poland, Belgium, Mexico, and Indonesia, extending its purchase-based, geo-targeted audiences to new international markets. As privacy regulations tighten and identifiers like cookies decline, marketers need new ways to reach high-value consumers at scale. NIQ’s GeoPurchase Audiences address this challenge by helping marketers identify and target consumers based on demand, not just demographics. GeoPurchase audiences help marketers pinpoint geographic areas where consumers are most likely to purchase specific FMCG categories, brands, or sub-brands, so media investments can concentrate where retail opportunities are strongest. By focusing investments in priority locations, marketers can connect with the audiences that matter in the markets with the greatest opportunity. As a resu
Smartly Introduces Smartly Synapse, the Intelligent AI Orchestration Layer Powering Its Advertising Platform22.6.2026 12:00:00 CEST | Press release
Smartly Synapse powers Smartly’s agentic orchestration, providing marketers a faster, more intelligent way to plan, execute, and optimize millions of signals for better results Smartly today introduced Smartly Synapse, the intelligent AI orchestration and memory layer behind every Smartly AI Agent. Built on years of cross-channel creative, media and performance intelligence and continuously shaped by real-world outcomes, Smartly Synapse transforms millions of signals into actions that help marketers plan smarter, execute faster and drive stronger business results. Smartly Synapse creates a continuous performance loop where marketer intent, business context, campaign activity and outcomes continuously inform one another. Its shared intelligence and memory layer helps the system learn from every campaign, improving future recommendations, execution and performance. “Smartly Synapse is the intelligent AI orchestration and memory layer behind our AI agents. It augments Smartly’s existing p
Europe’s Original First Check Investor Seedcamp Raises $320 Million22.6.2026 11:23:00 CEST | Press release
First backer of Revolut, Wise, UiPath, Synthesia and Fluidstack brings nearly two decades of experience and conviction to Europe’s next frontier Expands US team to support founders building global giants from day one Raise is split across a $220m Core fund and $100m Select fund to back winners through Series B and beyond Backing founders at the very beginning - before the company or the theme is obvious Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now returned over 13x DPI to its Limited Partners, and Fund IV sits at over 5x net TVPI. The new capital is
Navan Invests in European Footprint with New Partnerships22.6.2026 10:01:00 CEST | Press release
New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced new integrations with European travel suppliers. Navan will add to its platform a direct New Distribution Capability (NDC) connection with Italy’s national air carrier, ITA Airways; overnight rail services in the UK with Caledonian Sleeper; and mobile-first car rental bookings in France with Virtuo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622904121/en/ New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe “We’re seeing incredible momentum across Europe, bookings to and from the continent are up year-over-year, and to truly serve the European market you have to continually invest locally,” said Michael Riegel, Chief Customer Officer at Navan. “By bringing ITA’s
Finalists Announced for the Second Edition of the Reply AI Music Contest, the International Competition Exploring the Relationship Between AI and Live Performance22.6.2026 10:00:00 CEST | Press release
The jury will announce the winners on Saturday, 4 July, on the stage of Kappa FuturFestival in Turin Music and artificial intelligence come together at the Reply AI Music Contest to explore the relationship between AI and live performance. The competition, created by Reply and organized in collaboration with Kappa FuturFestival — one of Europe’s leading festivals dedicated to electronic music and cultural innovation — announces the five finalists selected by an international jury of professionals from music and creative industries: Agoria, Max Cooper, Fleur Shore, Tini Gessler, Ali Demirel, Albi Scotti, Oliver Bohl and Sarah Grimaldi. The finalists represent a new generation of innovators using AI to explore new forms of integration between sound, visual arts and live performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622111182/en/ Finalists announced for the second edition of the Reply AI Music Contest, the inte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom